Following the 101st place in 2014 and the 97th place in 2015, Eisai China Inc., harvested the 92nd place in the 2016 China Top 100 Pharmaceutical Enterprises List announced by China National Pharmaceutical Industry Information Center. Mr. Zhang Jiekui, Senior Director of Policy Administration of Eisai China Inc., accepted the award on behalf of the company.
Medal won by Eisai China Inc.
Scene of the awarding ceremony
During more than 20 years‘ industrious endeavors, Eisai’s staff always sticks to the corporate philosophy to “give first thought to patients and their families, and to increasing the benefits health care provides”, continuously brings in high-quality pharmaceutical products, proactively expands and innovates the business models, roots in China and serves Chinese patients and their families. Along with the fast development in China market, led by the management team headed by the President, Mr. Kaneko Norio, and the General Manager, Ms. Feng Yanhui, Eisai‘s staff follows the core principles of “hhc, innovation, access, autonomy”, adheres strictly to the Compliance, and continuously carries out tasks, such as talent development, structure optimization, cost control, efficiency improvement, innovation encouragement and etc. Every Eisai’s employee spends at least 1% of their working time to contact the patients and profoundly feel their sufferings. Eisai is endeavoring to make itself a respectable “hhc” company in China.
Eisai has invested 230 million US dollars in total in China and established entities including Eisai China Holdings Ltd., Eisai (Suzhou) Trading Co., Ltd., Eisai (Liaoning) Pharmaceutical Co., Ltd., and etc., with registered capital of 78.54 million US dollars, nearly 2,000 employees and creating value worth over RMB 3 billion yuan every year. China region has become one of Eisai Group‘s global Top 5 independent regions and contributes 8% to the group’s global sales, ranking the 3rd place, just following Japan and the US market. Eisai kept two-digit growth in 2014, 2015 and 2016, and has been the top 1st Japanese pharmaceutical company in China for nearly 10 successive years.
Eisai has identified neurology and oncology as important areas, and focus on marketing campaigns in 4,800 hospitals in over 100 cities with population of more than one million. In the future, Eisai will further strengthen its strategic production pipelines, penetrate into the lower market, bring in more high-quality drugs in the central neurology and oncology areas, and continuously provide high-quality generic drugs through Eisai (Liaoning) Pharmaceutical Co. Ltd. to better satisfy the needs of Chinese patients.